Modulation of metabolic changes in patients with heart failure by selective inhibition of 3-ketoacyl coenzyme A thiolase
نویسندگان
چکیده
A direct approach to manipulating cardiac energy metabolism consists of modifying substrate utilization by the heart. Pharmacological agents that directly inhibit fatty acid oxidation include inhibitors of 3-ketoacyl coenzyme A thiolase, the last enzyme involved in b-oxidation. The most extensively investigated agent of this group of drugs is trimetazidine. Clinical studies have shown that trimetazidine can substantially increase the ischemic threshold in patients with effort angina. However, the results of current research also support the concept that shifting the energy substrate preference away from fatty acid metabolism and toward glucose metabolism by the use of trimetazidine could be an effective adjunctive treatment in patients with heart failure, in terms of improvement in left ventricular and endothelial function and glucose metabolism. The recent literature on the protective effects of this new class of drugs on left ventricular dysfunction is reviewed and discussed. Heart Metab. 2006;33:21–24.
منابع مشابه
From recurrent ischemia to ischemic heart failure: new data on trimetazidine
Over recent years, the management of chronic coronary disease has improved markedly as a result of the increased use of surgical and percutaneous revascularization procedures. However, the prevalence of recurrent ischemia, together with the growing population of individuals surviving acute coronary syndromes but with serious myocardial damage, increases the prevalence of ischemic left ventricul...
متن کاملEffect of selective 3-ketoacyl coenzyme A thiolase inhibition on glucose metabolism in cardiac patients
It has recently been shown that trimetazidine, a 3-ketoacyl coenzyme A thiolase inhibitor, improves overall glucose metabolism in diabetic patients with left ventricular dysfunction. Forearm glucose and lipid metabolism and forearm release of endothelial vasodilator and vasoconstrictor factors during prolonged partial inhibition of fatty acid oxidation by trimetazidine have recently been evalua...
متن کاملMetabolic mechanisms associated with antianginal therapy.
Laboratory investigations into preserving viability of the ischemic myocardium or to promote recovery during reperfusion have often focused on the intermediary pathways of energy metabolism. However, in the clinical treatment of angina, the application of metabolic therapies has generally lagged behind or has been incidental to other approaches, such as a vasodilators, calcium antagonists, and ...
متن کامل4-Bromocrotonic Acid, an Effective Inhibitor of Fatty Acid Oxidation and Ketone Body Degradation in Rat Heart Mitochondria ON THE RATE-DETERMINING STEP OF P-OXIDATION AND KETONE BODY DEGRADATION IN HEART*
4-Bromocrotonic acid was found to effectively inhibit respiration supported by either palmitoylcarnitine or acetoacetate in coupled rat heart mitochondria. Partial inhibition was observed when 3-hydroxybutyrate served as a substrate, whereas pyruvate-supported r spiration was unaffected by the inhibitor. Thus, 4-bromocrotonic acid inhibits fatty acid oxidation a d ketone body degradation. W...
متن کاملThe antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
Trimetazidine acts as an effective antianginal clinical agent by modulating cardiac energy metabolism. Recent published data support the hypothesis that trimetazidine selectively inhibits long-chain 3-ketoacyl CoA thiolase (LC 3-KAT), thereby reducing fatty acid oxidation resulting in clinical benefit. The aim of this study was to assess whether trimetazidine and ranolazine, which may also act ...
متن کامل